YahooAugust 24, 2026 at 6:41 AM NY11 days ago
BofA starts bullish Alvotech coverage on biosimilar launch cycle
Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Exploring the top movers within the S&P500 index during today's session.
ChartMill1 hour ago
Sector Update: Financial
Yahoo3 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo3 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill3 hours ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill3 hours ago